What's new

Human medicines European public assessment report (EPAR): Cinqaero, reslizumab, Date of authorisation: 15/08/2016, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Cinqaero, reslizumab, Date of authorisation: 15/08/2016, Revision: 12, Status: Authorised

Apr 11, 2025 - 15:54
 0
Human medicines European public assessment report (EPAR): Cinqaero, reslizumab, Date of authorisation: 15/08/2016, Revision: 12, Status: Authorised
Human medicines European public assessment report (EPAR): Cinqaero, reslizumab, Date of authorisation: 15/08/2016, Revision: 12, Status: Authorised
Read More

Tags:

Previous Article

Fairmont Dallas Hotel Sold by Xenia Hotels & Resorts for $111 Million

Next Article

As Tesla EV Sales Dip, Lucid Looks To Expand And Tesla Enters Saudi Arabia

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Litfulo, Ritlecitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0026/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 14, 2025  0

COVID-19 vaccines: key facts

COVID-19 vaccines: key facts

Apr 11, 2025  0

Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 5, 2025  0